研究業績

2011年以降の主な研究業績

書籍

Yamanaka R (ed.), Primary Central Nervous System Lymphoma (PCNSL): Incidence, Management and Outcomes, Nova Science Publishers, New York, 2016.

Yamanaka R (ed.), Glioma: Immunotherapeutic approaches. Springer-Verlag, New York, 2012.

学術論文

Takashima Y, Kawaguchi A, Fukai J, Iwadate Y, Kajiwara K, Hondoh H, Yamanaka R. Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma. PLoS One16(6): e0251272, 2021. doi: 10.1371/journal.pone.0251272.
Takashima Y, Hamano M, Fukai J, Iwadate Y, Kajiwara K, Kobayashi T, Hondoh H, Yamanaka R. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. Sci Rep10(1):8435, 2020. doi: 10.1038/s41598-020-65463-6.
Takashima Y, Hayano A, Yamanaka R. Metabolome analysis reveals excessive glycolysis via PI3K/AKT/mTOR and RAS/MAPK signaling in methotrexate-resistant primary CNS lymphoma-derived cells. Clin Cancer Res 26 (11): 2754-2766,2020. doi: 10.1158/1078-0432.CCR-18-3851.
Takashima Y, Kawaguchi A, Iwadate Y, Hondoh H, Fukai J, Kajiwara K, Hayano A, and Yamanaka R. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma. PLoS One 15 (2): e0229577, 2020. doi: 10.1371/journal.pone.0229577.
Takashima Y, Kawaguchi A, Yamanaka R. Promising prognosis marker candidates on the status of epithelial-mesenchymal transition and glioma stem cells in glioblastoma. Cells 8(11):1312,2019. doi: 10.3390/cells8111312.
Takashima Y, Yoshimura T, Kano Y, Hayano A, Hondoh H, Ikenaka K, Yamanaka R. Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells. BMC Cancer 19(1):910,2019. doi: 10.1186/s12885-019-6129-8.
Takashima Y, Kawaguchi A, Sato R, Yoshida K, Hayano A, Homma J, Fukai J, Iwadate Y, Kajiwara K, Ishizawa S, Hondoh H, Nakano M, Ogawa S, Tashiro K, Yamanaka R. Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis predictin in PCNSL. Sci Rep 9(1):10004,2019. doi: 10.1038/s41598-019-46473-5.
Takashima Y, Kawaguchi A, Hayano A, Yamanaka R. CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma. PLoS One 14(5):e0216825,2019. doi: 10.1371/journal.pone.0216825.
Hayano A, Takashima Y, Yamanaka R. Cell-type specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells. Int J Clin Oncol 24(9):1020-1029, 2019. doi: 10.1007/s10147-019-01451-9.
Takashima Y, Kawaguchi A, Iwadate Y, Hondoh H, Fukai J, Kajiwara K, Hayano A, and Yamanaka R. MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma. PLoS One 14(1):e0210400, 2019. doi: 10.1371/journal.pone.0210400.
Yamanaka R, Hayano A, Takashima Y. Trilateral retinoblastoma: a systematic review of 211 cases. Neurosurg Rev 42(1):39-48,2019. doi: 10.1007/s10143-017-0890-4.
Tamura S, Sakaguchi K, Yamanaka R. Concerns and return to work in patients with breast cancer receiving outpatient chemotherapy: A pilot study. Asia Pac J Oncol Nurs 6(2):187-192, 2019. doi: 10.4103/apjon.apjon_58_18.
Takashima Y, Sasaki Y, Hayano A, Homma J, Fukai J, Iwadate Y, Kajiwara K, Ishizawa S, Hondoh H, Tokino T, Yamanaka R. Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. Oncotarget 9(44):27471-27486, 2018. doi: 10.18632/oncotarget.25463.
Takashima Y, Kawaguchi A, Kanayama T, Hayano A, Yamanaka R. Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. Oncotarget 9(27): 19065-19078, 2018. doi: 10.18632/oncotarget.24897.
Yamada C, Iwawaki Y, Harada K, Fukui M, Morimoto M, Yamanaka R. Frequency and risk factors for subsyndromal delirium in an intensive care unit. Intensive Crit Care Nurs 47:15-22, 2018. doi: 10.1016/j.iccn.2018.02.010.
Yamanaka R, Hayano A, Kanayama T. Radiation-induced gliomas: A comprehensive review and meta-analysis. Neurosurg Rev 41(3):719-731,2018. doi: 10.1007/s10143-016-0786-8.
Miyasato Y, Takashima Y, Takeya H, Yano H, Hayano A, Nakagawa T, Makino K, Takeya M, Yamanaka R, Komohara Y. The expression of PD-1 ligands and IDO1 by macrophages/microglia in primary central nervous system lymphoma. J Clin Exp Hematop 58(2):95-101,2018. doi: 10.3960/jslrt.
Yamanaka R, Morii K, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tsukamoto Y, Ogura R, Natsumeda M, Aoki H, Akiyama K, Saitoh T, Tamura T, Hondoh H, Kawaguchi A, Takahashi H, and Fujii Y. Late relapse of primary central nervous system lymphoma. Leukemia Lymphoma 58(2):475-477, 2017. doi: 10.1080/10428194.2016.1201570.
Fujimoto S, Iwawaki Y, Takishita Y, Yamamoto Y, Murota M, Yoshioka S, Hayano A, Hosokawa T, Yamanaka R. Effects and safety of mechanical bathing as a complementary therapy for terminal stage cancer patients from the physiological and psychological perspective: A pilot study. Jpn J Clin Oncol 47(11):1066-1072, 2017. doi: 10.1093/jjco/hyx122.
Yamanaka R, Morii K, Sano M, Homma J, Yajima N, Tsukamoto Y, Ogura R, Natsumeda M, Aoki H, Akiyama K, Saitoh T, Hondoh H, Kawaguchi A, Takahashi H, and Fujii Y. Long-term survivors of primary central nervous system lymphoma. Jpn J Clin Oncol 47(2): 101-107, 2017. doi: 10.1093/jjco/hyw171.
Yamanaka R, Hayano A. Radiation-induced malignant peripheral nerve sheath tumors: a systematic review. World Neurosurg 105:961-970.e8, 2017. doi: 10.1016/j.wneu.2017.06.010.
Yamanaka R, Hayano A. Radiation-induced schwannomas and neurofibromas: a systematic review. World Neurosurg 104:713-722, 2017. doi: 10.1016/j.wneu.2017.05.066.
Yamanaka R, Hayano A. Secondary craniofacial sarcomas following retinoblastoma: a systematic review. World Neurosurg 101:722-730.e4, 2017. doi: 10.1016/j.wneu.2017.02.031.
Yamanaka R, Hayano A. Radiation-induced sarcomas of the central nervous system: a systematic review. World Neurosurg 98:818-828, 2017. doi: 10.1016/j.wneu.2016.11.008.
Yamanaka R, Hayano A, Kanayama T. Radiation-induced meningiomas: an exhaustive review of the literature. World Neurosurg 97:635-644,2017. doi: 10.1016/j.wneu.2016.09.094.
Yamanaka R, Abe E, Sato T, Hayano A and Takashima Y. Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review. Cancers (Basel) 9(8): 2017. doi: 10.3390/cancers9080103.
Hayano A, Komohara Y, Takashima Y, Takeya H, Homma J, Fukai J, Iwadate Y, Kajiwara K, Ishizawa S, Hondoh H and Yamanaka R. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. Anticancer Res 37(10):5655-5666, 2017. doi: 10.21873/anticanres.12001.
Yamanaka R, Hayano A. Secondary glioma following acute lymphocytic leukemia: Therapeutic implications. Neurosurg Rev 40(4):549-557, 2017. doi: 10.1007/s10143-016-0733-8.
Ma C, Horlad H, Pan C, Yano H, Ohnishi K, Fujiwara Y, Matsuoka M, Lee A, Niidome T, Yamanaka R, Takeya M, Komohara Y. Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. J Clin Exp Hematop 57(1):21-25, 2017. doi: 10.3960/jslrt.17006.
Nakajima S, Morii K, Takahashi H, Fujii Y, Yamanaka R. Prognostic significance of S-phase fractions in peritumoral invading zone analyzed by laser scanning cytometry in patients with high-grade glioma (preliminary study). Oncol Lett 11(3):2106-2110,2016. doi: 10.3892/ol.2016.4205.
Koyama-Nasu R, Hayashi T, Nasu-Nishimura Y, Akiyama T and Yamanaka R. Thr160 of Axin1 is critical for the formation and function of the β-catenin destruction complex. Biochemical Biophysical Res Comm 459(3):411-415, 2015. doi: 10.1016/j.bbrc.2015.02.118.
Hasegawa M, Hayano A, Kawaguchi A and Yamanaka R. Assessment of autonomic nervous system function in nursing students using an autonomic reflex orthostatic test by heart rate spectral analysis. Biomedical Reports 3:831-834,2015. doi: 10.3892/br.2015.512.
Yamanaka R, Hayano A. Experiences and prospective expectations for glioma immunotherapeutic approaches. Front Oncol 4:355, 2014. doi: 10.3389/fonc.2014.00355.
Iwadate Y, Suganami A, Ikegami S, Shinozaki N, Matsutani T, Tamura Y, Saeki N, Yamanaka R. Non-deep-seated primary CNS lymphoma – therapeutic responses and a molecular signature. J Neurooncol 117(2):261-268, 2014. doi: 10.1007/s11060-014-1379-4.
Kawaguchi A, Yajima N, Tsuchiya N, Homma J, Sano M, Natsumeda M, Takahashi H, Fujii Y, Kakuma T, Yamanaka R. Gene expression signature-based prognostic risk score in patients with glioblastoma.Cancer Sci 104(9):1205-1210, 2013. doi: 10.1111/cas.12214.
Kon T, Natsumeda M, Takahashi H, Taki T, Fujii Y, Yamanaka R. Radiation-induced glioblastoma following radiotherapy for pituitary adenomas: marked response to chemotherapy. J Neurol Neurophysiol 4: 155, 2013. doi:10.4172/2155-9562.1000155.
Takahashi R, Ishibashi Y, Hiraoka K, Matsueda S, Kawano K, Kawahara A, Kage M, Ohshima K, Yamanaka R, Shichijo S, Shirouzu K, Itoh K, Sasada T. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. Cancer Sci 104(10):1285-1294, 2013. doi: 10.1111/cas.12226.
Kawaguchi A, Iwadate Y, Komohara Y, Sano M, Kajiwara K, Yajima N, Tsuchiya N, Homma J, Aoki H, Kobayashi T, Sakai Y, Hondoh H, Fujii Y, Kakuma T, Yamanaka R. Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma. Clin Cancer Res 18(20):5672-5681,2012. doi: 10.1158/1078-0432.CCR-12-0596.
Kawaguchi A, Yajima N, Komohara Y, Aoki H, Tsuchiya N, Homma J, Sano M, Natsumeda M, Uzuka T, Saitoh A, Takahashi H, Sakai Y, Takahashi H, Fujii Y, Kakuma T, Yamanaka R. Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. Int J Oncol 40(3):721-730,2012. doi: 10.3892/ijo.2011.1240.
Yamanaka R, Koga H, Yamamoto Y, Yamada S, Sano T, Fukushige T. Characteristics of patients with brain metastases from lung cancer in a palliative care center. Support Care Cancer 19(4):467-473,2011. doi: 10.1007/s00520-010-0838-5.
Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 10(12):1266-1279, 2011. doi: 10.4161/cbt.10.12.13448.
Komohara Y, Horlad H, Ohnishi K, Ohta K, Makino K, Hondo H, Yamanaka R, Kajiwara K, Saito T, Kuratsu J, Takeya M. M2 macrophage/microglial cells induce activation of stat3 in primary central nervous system lymphoma. J Clin Exp Hematop 51(2):93-99, 2011. doi: 10.3960/jslrt.51.93.